Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. [electronic resource] by
- Popejoy, Myra W
- Paterson, David L
- Cloutier, Daniel
- Huntington, Jennifer A
- Miller, Benjamin
- Bliss, Caleb A
- Steenbergen, Judith N
- Hershberger, Ellie
- Umeh, Obiamiwe
- Kaye, Keith S
Producer: 20170814
In:
The Journal of antimicrobial chemotherapy vol. 72
Availability: No items available.
|
|
10.
|
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. [electronic resource] by
- Kollef, Marin H
- Nováček, Martin
- Kivistik, Ülo
- Réa-Neto, Álvaro
- Shime, Nobuaki
- Martin-Loeches, Ignacio
- Timsit, Jean-François
- Wunderink, Richard G
- Bruno, Christopher J
- Huntington, Jennifer A
- Lin, Gina
- Yu, Brian
- Butterton, Joan R
- Rhee, Elizabeth G
Producer: 20200615
In:
The Lancet. Infectious diseases vol. 19
Availability: No items available.
|